Rocket Lab at 73x Revenue, Archer at Pre-Revenue: The Math on Both Is Hard to Swallow

A recent market note called Rocket Lab a "high-conviction stock" and Archer Aviation a "bad bet." The verdict sounds confident. The math behind both labels is worth testing, because the same valuation discipline that makes one look like a stretch should make the other look like a trap.

The disconnect at Rocket Lab is not whether the company can grow. It's whether anything justifies 73x sales.

Rocket Lab's Q1 2026 results were real. Revenue hit $200.35 million, up 63.5% from the prior-year quarter. Gross margin reached a record 38.2% on a GAAP basis. The backlog surged to $2.2 billion, up 20% quarter over quarter. Five new Neutron launch contracts were signed — the first dedicated orders for the medium-lift rocket still in development. Total contracted missions now exceed 70.

The operational trajectory is the kind of ramp the growth narrative is built on. Q2 2026 revenue guidance of $225 million to $240 million implies the company is on track for well over $800 million in full-year 2026 revenue, a substantial step up from the $601.8 million it posted in all of 2025.

The problem is the price tag. Rocket Lab's market cap sits at roughly $49.5 billion. That is 73 times trailing sales and 71 times enterprise value-to-sales, for a company that burned through $316 million in free cash flow over the last twelve months. Forward EPS estimates are still negative through at least mid-2026 — consensus has the company losing $0.058 per share in Q2, with losses expected to persist through Q3. AInvest's aggregate rating consensus labels the stock a Buy, but consensus doesn't print money when the multiple assumes perfection for a decade.

The Neutron rocket is the only thing that can justify this number. It's a reusable medium-lift vehicle designed to carry 13,000 kg to low Earth orbit, a 43x payload increase over the Electron. If it flies in 2026 and converts letters of intent into firm contracts, significant Neutron revenue could show up in 2027–2028. The company already has the Department of Defense's Space Based Interceptor program and an expanded role in the MACH-TB hypersonic testing contract as proof that defense customers are writing checks.

But 73x revenue means the market has already priced in Neutron success, rapid adoption, margin expansion, no delays, and no competition eating share. That's not a growth story — that's a guarantee. The stock needs Neutron to not just fly but to win commercial and defense contracts at scale, within the expected timeline, at margins that support this market cap. One delay, one cost overrun, one competitor undercutting price, and the multiple collapses.

AInvest's aggregate signal labels Rocket Lab a Buy, but that rating is testing whether investors are buying a space infrastructure company or a story priced for a decade of flawless execution.

Archer Aviation's problem is the opposite: there's no math to argue against.

Archer Aviation is building electric vertical takeoff and landing (eVTOL) aircraft — essentially autonomous air taxis. The Midnight aircraft is designed to carry a pilot and four passengers on routes of 20 to 50 miles at speeds up to 150 mph.

The financials are not the issue. There are no financials to defend. In Q1 2026, Archer reported $1.6 million in revenue, derived from leasing space at the Hawthorne airport it acquired in Los Angeles. That is not air taxi revenue. That is parking lot revenue. The company lost $0.28 per share in the quarter and guided for an adjusted EBITDA loss of $170 million to $200 million in Q2 2026.

Cash burn is running roughly $180 million per quarter. Archer held about $1.8 billion in liquidity as of mid-2026, which gives a runway of approximately 2.5 years. That runway assumes burn doesn't accelerate — and management's own Q2 guidance suggests strategic spending, including a defense partnership with Anduril, could push it higher. At that pace, dilution is not a risk. It's a certainty. The company already raised $650 million in equity during Q3 2025, and investors who bought at $14 will watch their stake shrink with each subsequent raise.

But the deeper problem is structural, not financial. Archer is still in Stage 4 of FAA type certification, the phase where actual flight and structural testing happens. The company has not yet flown an FAA-conforming aircraft. Competitor Joby Aviation flew its first conforming aircraft in March, putting Archer behind on the regulatory timeline. Management targets a piloted transition flight in the second half of 2026, but certification doesn't land on a calendar — it lands when the regulator says it's ready.

Two short reports — from Culper Research in May 2025 and Grizzly Research later that year — alleged the company misled investors on testing timelines and flight milestones. Grizzly specifically noted few signs that manufacturing was ramping. Archer's stock has fallen roughly 50% from its 52-week high, currently trading around $5.20 on a market cap of roughly $4.2 billion.

A $4.2 billion valuation for a company earning $1.6 million in quarterly revenue, with no FAA certification, no commercial flights, and a 2.5-year cash runway is not a mispriced opportunity. It's an option on regulatory approval, and options have expiration dates. Archer's expires when the cash runs out.

The verdict isn't that one is a buy and one is a sell. It's that neither passes the forward-multiple test.

The market note that crowned Rocket Lab a high-conviction pick was right about the growth and wrong about the valuation. The company is building something real, with real contracts, real margins, and a backlog that keeps growing. But 73x revenue for a company that isn't yet profitable and depends on an unflown rocket to deliver its growth inflection is not conviction. It's a hope premium.

And Archer is a hope premium without the revenue to justify it. The eVTOL thesis could work in theory, but theory doesn't pay $180 million in quarterly burn. Certification delays, competitive losses to Joby, and inevitable dilution make the $4.2 billion market cap a forward bet on regulatory luck, not business execution.

If Rocket Lab's Neutron launches on schedule, converts its backlog, and begins delivering margin expansion in 2027, the 73x multiple could work. The stock would need to find its bottom first — it's pulled back from a 52-week high of $151 to the low $80s, which is where the valuation starts to look like a growth premium instead of a moonshot. But that's a condition, not a guarantee.

Archer needs FAA certification, successful commercial operations, and at least two more equity raises before it generates meaningful air taxi revenue. Each dilutive raise pushes the breakeven further away.

Neither stock is a bargain. One is priced for perfection. The other is priced for a miracle.

Break condition for Rocket Lab: Neutron's first launch succeeds and the stock retraces below $60, where the EV/sales multiple drops into the 40x range and starts approaching something a growth company can earn. Break condition for Archer: FAA certification lands on schedule in 2026–2027 and commercial revenue clears $50 million annually without another dilutive raise. Until then, the math on both points to watching, not buying.